DOI 10.1080/14712598.2026.2650104
Advances in the management of giant cell arteritis-aortitis: biologic therapies and beyond - a narrative review.
Аннотация
INTRODUCTION
Giant cell arteritis (GCA) is the most common systemic vasculitis in individuals over 50 years of age. Aortic involvement is frequent, often clinically silent, and significantly increases the risk of thoracic aortic aneurysm, underscoring the need for early detection and optimal management.
AREAS COVERED: This review summarizes current knowledge on the pathophysiology, diagnosis, and management of GCA-related aortitis, with emphasis on Th17- and Th1-driven immune pathways and their therapeutic implications. A structured literature search was conducted in major medical databases, including PubMed/MEDLINE, focusing on studies addressing aortic involvement in GCA, imaging modalities for disease assessment, and therapeutic strategies such as glucocorticoids, conventional synthetic disease-modifying antirheumatic drugs, biologic agents, and Janus kinase inhibitors.
EXPERT OPINION: Management should follow a treat-to-target strategy aimed at achieving clinical and, when feasible, imaging remission. Although glucocorticoids remain the cornerstone of treatment, steroid-sparing approaches, particularly with tocilizumab, and emerging targeted biotherapies may improve long-term vascular outcomes and prognosis in selected patients.
Предметные рубрики MeSH
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.